AZ, Moderna say mRNA drug is promising in heart failureModerna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of Share XAZ, Moderna say mRNA drug is promising in heart failurehttps://pharmaphorum.com/news/az-moderna-say-mrna-drug-is-promising-in-heart-failure/
Smartphone-powered trial backs J&J’s Invokana for heart failureJohnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms Share XSmartphone-powered trial backs J&J’s Invokana for heart failurehttps://pharmaphorum.com/news/smartphone-powered-trial-backs-jjs-invokana-for-heart-failure/
AI could be used to guide drug therapy for heart failureUK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who Share XAI could be used to guide drug therapy for heart failurehttps://pharmaphorum.com/news/ai-could-be-used-to-guide-drug-therapy-for-heart-failure/
Jardiance gets parity with Farxiga in US as FDA clears use in heart failureEli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with Share XJardiance gets parity with Farxiga in US as FDA clears use in heart failurehttps://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/
FDA gives breakthrough status to Biofourmis’ heart failure DTxA digital therapeutic for patients with heart failure has been awarded breakthrough device status by the FDA – Share XFDA gives breakthrough status to Biofourmis’ heart failure DTxhttps://pharmaphorum.com/news/fda-gives-breakthrough-status-to-biofourmis-heart-failure-dtx/
First US patient gets total heart replacement with CARMAT deviceAn experimental artificial heart developed by French medical device specialist CARMAT has been implanted into the first of Share XFirst US patient gets total heart replacement with CARMAT devicehttps://pharmaphorum.com/news/first-us-patient-gets-total-heart-replacement-with-carmat-device/
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failureBoehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance Share XBoehringer, Lilly hail Jardiance data in hard-to-treat heart failurehttps://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/
AZ drug for hard-to-treat heart failure has mixed results in trialAstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction Share XAZ drug for hard-to-treat heart failure has mixed results in trialhttps://pharmaphorum.com/news/az-drug-for-hard-to-treat-heart-failure-has-mixed-results-in-trial/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
